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a b s t r a c t
The C-type lectin receptors (CLRs) expressed on dendritic cells (DCs), in particular DC-SIGN and DCIR,
likely play an important role in HIV-1 early infection. Here, we systematically compared the capture and
transfer capability of DC-SIGN and DCIR using a wide range of HIV-1 isolates. Our results indicated that
DC-SIGN plays a stronger role than DCIR in DC-mediated HIV-1 capture and transfer. This was further
strengthened by the data from transient and stable transfectants, showing that DC-SIGN had better
capability, compared with DCIR in HIV-1 capture and transfer. Following constructing and analyzing a
series of soluble DC-SIGN and DCIR truncates and chimeras, we demonstrated that the neck domain, but
not the CRD, renders DC-SIGN higher binding afﬁnity to gp120 likely via the formation of tetrameriza-
tion. Our ﬁndings provide insights into CLR-mediated HIV-1 capture and transfer, highlighting potential
targets for intervention strategies against gp120-CLR interactions.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The majority of HIV-1 infections are acquired by mucosal
exposure, with sexual transmission as the leading mode of HIV-1
infection worldwide (Haase, 2010; Royce et al., 1997). The anato-
mical distribution of dendritic cells (DCs) in the genital and anal
mucosa (Edwards and Morris, 1985; Miller et al., 1992) together
with the ﬁndings from in vitro studies (Masurier et al., 1998;
Taruishi et al., 2004; Wiley and Gummuluru, 2006) inform that
immature DCs are likely to be one of the ﬁrst cell types targeted by
HIV-1 (Harman et al., 2013; Hu et al., 2000; Wu and KewalRamani,
2006). Myeloid DCs are professional antigen presenting cells that
can capture microorganisms in the peripheral mucosal tissues and
then migrate to secondary lymphoid organs, where they present
these in antigenic form to resting T cells and thus initiate adaptive
immune responses (Banchereau et al., 2000; Banchereau and
Steinman, 1998; Valitutti et al., 1995). Such process could be
hijacked by HIV-1 to deliver itself from the mucosa to the
secondary lymphoid organs, described as in trans-transmission
or the “Trojan horse” model (Cameron et al., 1992; Izquierdo-
Useros et al., 2010; Wiley and Gummuluru, 2006). In addition, DCs
can also be directly infected by HIV-1 and transfer progeny viruses
to CD4þ T cells, named in cis-transmission (Nobile et al., 2005;
Turville et al., 2004). Given that HIV-1/SIV-infected DCs are rarely
detected in vivo (Spira et al., 1996; Steinman et al., 2003), extensive
in vitro studies imply that trans-infection likely plays a more
important role in HIV-1 early infection and dissemination
(McDonald, 2010; Piguet and Steinman, 2007).
The receptor CD4 and co-receptors CCR5 and CXCR4 utilized by
HIV-1 for infection are lowly expressed on DCs (Granelli-Piperno
et al., 1996; Turville et al., 2001). In contrast, the expression of
C-type lectin receptors (CLRs) on DCs is relatively high (Turville
et al., 2003). CLRs share a common sequence motif indicative of
similarly folded carbohydrate-recognition domain (CRD), which
can recognize carbohydrates in a calcium-dependent manner
(Feinberg et al., 2005; Zelensky and Gready, 2005). To date, a
range of CLRs have been shown to bind HIV-1 gp120, the heavily
glycosylated envelope protein with carbohydrates accounting for
as much as 50% of its mass (Quinones-Kochs et al., 2002; Soilleux
et al., 2002; Turville et al., 2003). Among the CLRs reported, DC-
speciﬁc intercellular adhesion molecule 3-grabbing non-integrin
(DC-SIGN) and DC immunoreceptor (DCIR), can bind gp120 and
consequently enhance trans- and cis-infection of HIV-1 (Baribaud
et al., 2001; Geijtenbeek et al., 2000; Lambert et al., 2008). DC-
SIGN, originally cloned from a placental cDNA library as a gp120
binding protein with a greater afﬁnity than CD4 (Curtis et al.,
1992), binds preferentially to N-linked high mannose glycans on
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gp120, resulting in DC-mediated HIV-1 in trans and in cis infec-
tions by affecting viral internalization and immune evasion (Cambi
et al., 2009; Pohlmann et al., 2001; van den Berg and Geijtenbeek,
2013). On the other hand, gp120 is also reported to be recognized
by DCIR, a novel type II transmembrane molecule of the CLR family
containing a consensus intracellular immunoreceptor tyrosine-
based inhibitory motif (ITIM) (Bates et al., 1999; Lambert et al.,
2008). DCIR expression on CD4þ T cells can be induced by HIV-1,
and the ITIM-associated signal transduction pathway is necessary
in DCIR-mediated enhancement of HIV-1 infection (Lambert et al.,
2010, 2011). However, the carbohydrate structure on gp120
recognized by DCIR is unclear (Lambert et al., 2013). Furthermore,
the importance of DC-SIGN in HIV-1 infection remains controver-
sial (Boggiano et al., 2007; da Silva et al., 2011; Gummuluru et al.,
2003). Given that DC-SIGN and DCIR both function in gp120
binding, we asked whether these two CLRs contribute equally or
one over the other in DC-mediated HIV-1 capture and transfer.
Here we systematically compared the capability of DC-SIGN
and DCIR in HIV-1 capture and transfer at cellular and biochemical
levels. Our results indicate that both DC-SIGN and DCIR can
capture and transfer HIV-1 independent of viral isolates, with
DC-SIGN showing better capability than DCIR. Further study using
DC-SIGN and DCIR truncates and chimeras reveal that the tetra-
merization structure likely plays an important role in the DC-
SIGN-mediated enhancement of HIV-1 capture and transfer.
Results
Knockdown of DC-SIGN expression on iMDDCs signiﬁcantly decreases
HIV-1 capture and transfer
To address the proportional contribution of DC-SIGN and DCIR
in DC-mediated HIV-1 capture and transfer, we used immature
monocyte derived dendritic cells (iMDDCs) as a model. iMDDCs
have been widely used in studies to mimic DCs and may also have
in vivo relevance. For instance, monocytes were observed to
develop into iMDDCs at sites of inﬂammation as a second recruit-
ment of antigen-presenting cells (Randolph et al., 1999). After
the differentiation of monocytes into iMDDCs, we analyzed
the expression levels of HIV-1 related receptors by FACS. Consis-
tent with results from previous studies by others (Turville et al.,
2001), the expression of CD4 and CCR5 on iMDDCs was very low,
while the levels of C-type lectin receptors (CLRs), including DC-
SIGN and DCIR, were relatively high (Fig. 1A). To investigate the
contribution of DC-SIGN and DCIR in HIV-1 capture and transfer,
DC-SIGN or DCIR speciﬁc siRNA was used to knockdown the
expression of corresponding CLRs. After speciﬁc siRNA treatment,
the surface expression of DC-SIGN and DCIR decreased to a similar
percentage level, with approximately 40% of expression by mean
ﬂuorescence intensity (MFI) or 35% of expression by relative value
to β-actin compared to control groups (Fig. 1B–D). Results from
HIV-1 capture assay showed that iMDDCs with DC-SIGN or DCIR
knockdown both demonstrated decreased capability in capturing
HIV-1 BaL, showing 60% and 40% reduction in mediating HIV-
1 capture, respectively (Fig. 1E). Although results slightly differed
among different donors, the trends were similar, showing that
iMDDCs with DC-SIGN knockdown had less capability in HIV-1
capture than those with DCIR knockdown (Fig. S1). Similar results
were observed in HIV-1 transfer experiments (Fig. 1F).
DC-SIGN demonstrates stronger capability than DCIR in HIV-1
capture and transfer
To investigate the capability of DC-SIGN and DCIR in mediating
HIV-1 capture and transfer, 293T and QT6 cells transiently
expressing DC-SIGN or DCIR were initially used for HIV-1 capture
and transfer experiments. DC-SIGN and DCIR expressions on 293T
and QT6 cells at the time of assay were determined by FACS,
showing that the surface expression levels of the two CLRs were
similar (Fig. 2A). Considering that antibody used for DCIR detec-
tion may have a different afﬁnity to that used for DC-SIGN
detection, we further conﬁrmed the expression of DC-SIGN and
DCIR by engineering ﬂag labeled constructs. Flag was introduced
to the N terminal of DC-SIGN and DCIR, and the expression was
determined by western blotting using anti-ﬂag antibody. Consis-
tent with the results from FACS, western blotting data showed that
the two proteins were expressed at similar levels on all the tested
cell lines (Fig. S2). Following expression determination, 293T and
QT6 cells expressing DC-SIGN or DCIR were used to examine their
capability in HIV-1 capture and transfer. As shown in Fig. 2B and C,
both DC-SIGN and DCIR, regardless of cell types, demonstrated the
capability in capturing and transferring HIV-1 BaL. The effect could
be blocked by mannan (Fig. 2) while kifunensine (Eggink et al.,
2010) enhanced the effect of DC-SIGN but not DCIR in HIV-1
capture (data not shown), indicating a speciﬁc interaction between
CLR and the glycans of HIV-1 Env. Moreover, DC-SIGN possessed
considerably stronger ability than DCIR in both capture and
transfer experiments. Further assessment showed that this cap-
ability of HIV-1 capture by CLR-expressing cells was dose depen-
dent and a speciﬁc interaction between CLRs and HIV-1 Env was
necessary (Fig. S3).
We next conﬁrmed the results using DC-SIGN or DCIR stably
expressing Raji cells. Raji cell line is a CD4 and lectin-negative
human B-cell line, and Raji-DC-SIGN has been widely used in
previous studies (Wu et al., 2004). In the current study, we
generated DCIR-expressing stable cell line. DC-SIGN and DCIR
were expressed at comparable levels on stable Raji cells as
assessed by FACS (Fig. 2A). The results in HIV-1 capture and
transfer assays were consistent with those obtained from 293T
and QT6 cells, revealing that both DC-SIGN and DCIR possessed the
ability in capturing and transferring HIV-1 BaL, with the capability
of DC-SIGN higher than that of DCIR (Fig. 2D).
DC-SIGN is more efﬁcient than DCIR in capturing a wide range
of HIV-1 isolates
After demonstrating that DC-SIGN and DCIR are both capable of
capturing and transferring HIV-1 BaL, with DC-SIGN possessing
better capability than DCIR, we further conducted capture experi-
ments using a wide range of HIV-1 isolates including laboratory-
adapted strains, primary isolated as well as transmitted/founder
(T/F) Env-pseudotyped and infectious viruses, speciﬁed as follows:
IIIB, a laboratory-adapted X4 clone; MWS2 env, cloned from semen
of a subject known to have infected women by vaginal inter-
course; CH811 env, cloned from a blood sample isolated from a
Chinese patient; and T/F HIV-1 clones, isolated very early after
transmission and thought to be more physiologically relevant than
laboratory-adapted strains (Keele et al., 2008). As shown in Fig. 3,
in general, both DC-SIGN and DCIR expressing Raji cells were
capable of capturing the tested HIV-1 isolates, with DC-SIGN
demonstrating much stronger capability than DCIR, although
slight differences were observed when different viruses were
tested. Moreover, DC-SIGN, but not DCIR, seemed to have better
capability in capturing HIV-1 infectious viruses than Env-
pseudotyped viruses (Fig. 3B). Of note, DCIR-expressing cells failed
to show signiﬁcant increase in capturing several T/F strains
(Fig. 3C), compared to the parental Raji cells. In addition, iMDDCs
with DCIR knock-down showed large (BaL), moderate (CH042.C)
and small (REJO.D12.1972) reduction in HIV-1 capture. In contrast,
DC-SIGN knock-down severely impaired the capture of all the
three tested viruses by iMDDCs (Fig. S4). Taken together, results
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herein indicate that, although DC-SIGN and DCIR can both capture
HIV-1, DC-SIGN is more efﬁcient than DCIR.
Tetramerization renders DC-SIGN higher binding afﬁnity to gp120
The binding of CLR CRD to gp120 glycans was reported to be the
main mechanism underlying CLR-mediated HIV-1 capture and
transfer (Mesman and Geijtenbeek, 2012). DC-SIGN and DCIR are
both type II transmembrane molecules of the CLR family, with
conserved regions and residues and similarly folded structure in
CRD (Zelensky and Gready, 2005). Previous studies have demon-
strated that DC-SIGN binds preferentially to N-linked high mannose
glycans on gp120, while the carbohydrate structure on gp120
recognized by DCIR remains unclear (Curtis et al., 1992; Lambert
et al., 2013; Su et al., 2004). Our results above reveal that DC-SIGN
possesses better capability in both HIV-1 capture and transfer than
DCIR. Considering that CRD is the key domain interacting with
gp120 glycans, we ﬁrst compared the binding afﬁnity of DC-SIGN
and DCIR CRDs to HIV-1 gp120. We designed, expressed, puriﬁed
and characterized a series of soluble proteins as follows: soluble DC-
SIGN and soluble DCIR which contains the whole extracellular
regions including the neck domain and CRD of corresponding CLR;
soluble DC-SIGN CRD and soluble DCIR CRD containing correspond-
ing CRD. The results showed that soluble DCIR, DCIR CRD and DC-
SIGN CRD demonstrated similar binding afﬁnities to HIV-1 gp140,
with similar KD, Kon and Kdis values. Soluble DC-SIGN, on the other
hand, had smaller KD and Kdis and larger Kon, indicating that soluble
DC-SIGN bound to gp140 in a strong and steady way compared with
the other three proteins (Table 1 and Fig. S5). These results together
imply that CRD is not the sole determinant accounting for the
distinct binding afﬁnities of DC-SIGN and DCIR to gp120.
In addition to CRD, another main difference between DC-SIGN
and DCIR is that DC-SIGN, but not DCIR, contains a neck domain
composed of several repeat regions which can mediate protein
Fig. 1. DC-SIGN or DCIR knockdown on iMDDCs decreases DC-mediated HIV-1 capture and transfer. (A) Expression levels of HIV-1 related receptors on iMDDCs were
analyzed by FACS. One representative experiment from one donor out of six is shown. (B–D) siRNA knockdown of DC-SIGN or DCIR on iMDDCs. 1106 iMDDCs were either
untreated, or transfected with control siRNA, DC-SIGN or DCIR speciﬁc siRNA for 48 h. (B) The expression level of DC-SIGN and DCIR was assessed by FACS. One
representative experiment from one donor out of six is shown. (C) After 48 h siRNA treatment, cells were lysed and the cell lysates were measured by west blotting, using
speciﬁc antibody and HRP conjugated secondary antibody. One representative experiment from one donor out of three is shown. Knockdown efﬁcacy was depicted as the
percentage of the mean ﬂuorescence intensity (MFI) or relative value to β-actin of the untreated samples. Mean7SEM of three independent experiments is shown (D).
(E and F) Knockdown of DC-SIGN or DCIR on iMDDCs affects HIV-1 capture and transfer. After siRNA knockdown treatment, 1106 iMDDCs were incubated with 100 ng p24
of HIV-1 pNL4-3 BaLþ at 37 1C for 2 h. Cells were extensively washed to remove unbound virus and HIV-1 capture was measured by HIV-1 p24, using untreated samples as
controls. Data shown are mean7SEM of experiments from six donors with each condition performed in triplicate in each donor (E). For virus transfer assay, washed cells
were co-cultured with autologous PBMCs (1:3 ratio) at 37 1C. The supernatants were collected every 3 days and p24 were determined. Data shown are mean7SEM of
experiments from six donors with each condition performed in triplicate in each donor (F). (*po0.05; **po0.01).
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tetramerization (Feinberg et al., 2005). We have previously
demonstrated the role of the neck domain in DC-SIGN tetramer-
ization (Du et al., 2012). It is likely that tetramerization renders
DC-SIGN better gp120 binding activity over DCIR. To test this
hypothesis, monomeric DC-SIGN and tetrameric DCIR were con-
structed by exchanging respective extracellular neck domains and
the expression of engineered constructs was conﬁrmed by western
blotting (Fig. S6). Following HIV-1 capture analyses, the results
showed that the ability of monomeric DC-SIGN in HIV-1 capture
was severely impaired to a level similar to that of monomer DCIR,
indicating that the tetrameric structure of DC-SIGN plays an
important role in DC-SIGN-mediated HIV-1 binding (Fig. 4).
The tetrameric DCIR did not show signiﬁcant increase in HIV-1
capture over the monomeric DCIR, which was likely due to
inappropriate conformational rearrangement of the chimeric pro-
tein (Fig. 4).
Intact CRD structure is important for DC-SIGN mediated HIV-1
capture
To further conﬁrm the role of CRD in DC-SIGN, we constructed
three DC-SIGN chimeras (N-chimera 1, 2, 3) by mutating some
amino acids in the long loop region, according to the sequence of
DCIR (Fig. 5A). The long loop region, structurally and evolutionarily
ﬂexible, is a characteristic structure in the CRD of the type II
lectins, which has two Ca2þ-binding sites involving in Ca2þ-
dependent carbohydrate binding (Zelensky and Gready, 2005).
Within this region, the EPN motif (Glu-Pro-Asn) in DC-SIGN is
speciﬁc for mannose recognition (Baribaud et al., 2001;
Pokidysheva et al., 2006), while the EPS motif (Glu-Pro-Ser)
in DCIR for galactose recognition (Richard et al., 2003). As shown
in Fig. 5, compared with the intact DC-SIGN, the capability in HIV-
1 capture of N-chimeras 1, 2 and 3 all considerably decreased.
Fig. 2. DC-SIGN demonstrates stronger capability than DCIR in HIV-1 capture and transfer. (A) DC-SIGN or DCIR expression on 293T (left), QT6 (middle), Raji (right) cells was
analyzed by FACS. 293T and QT6 cells were transfected with pcDNA3.1, DC-SIGN or DCIR expressing plasmids for 48 h. The stable Raji cell populations that express DC-SIGN
or DCIR were generated as described in Materials and methods. (B–D) Capability of DC-SIGN or DCIR expressing cells in mediating HIV-1 capture and transfer. 1106 293T
(B) or QT6 (C) cells transfected with DC-SIGN or DCIR expression plasmid for 48 h, or DC-SIGN or DCIR stably expressing Raji cells (D) were pre-incubated in the presence or
absence of mannan (5 mg/ml) at 37 1C for 1 h before exposure to Env-pseudotyped virus stocks. Following incubation at 37 1C for another 2 h, unbound viruses were
extensively washed with PBS. For HIV-1 capture assay (left), washed cells were lysed directly and p24 was measured. For virus transfer assay (right), washed cells were co-
cultured with U87-CD4.CCR5 cells at 37 1C for 48 h. Cells were lysed and luciferase activity was determined. 293T or QT6 cells transfected with pcDNA3.1, or parental Raji
cells were used as controls and the activity was expressed as control %. Data shown are mean7SD of six independent experiments with each condition performed in
triplicate. (*po0.05; **po0.01).
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N-chimera 3 almost completely lost the capability in mediating
HIV-1 capture. These data indicate that not only the tetrameric
structure but also the intact CRD structure is essential for DC-SGN
mediated HIV-1 capture.
Discussion
Among the surface components on DCs involved in HIV-1
binding, CLRs that recognize the carbohydrates of gp120, are
potentially important in mucosal HIV-1 infection (Rinaldo, 2013;
Turville et al., 2003). Our current study focused on the capability of
two members of type II CLRs, DC-SIGN and DCIR, in HIV-1 capture
and transfer. We demonstrate that DC-SIGN plays a stronger role
than DCIR in DC-mediated HIV-1 capture and transfer and that the
DC-SIGN neck domain renders DC-SIGN higher binding afﬁnity to
gp120 likely through tetramerization formation.
The mucosal transmission rate of HIV-1 is inefﬁcient and only a
small amount of virions can pass the mucosal barrier to encounter
target cells (Bobardt et al., 2007; deWitte et al., 2008). Therefore,
any potential selective advantages acquired by HIV-1, such as
enhanced binding by attachment receptors, might signiﬁcantly
increase the chances of a successful transmission event. Using DCs
and constructed CLR-expressing cells lines as models, we demon-
strated that DC-SIGN had a stronger capability compared with
DCIR in HIV-1 capture and transfer regardless of HIV-1 strains
used. In contrast to DC-SIGN, DCIR showed little activity in
capturing several T/F HIV-1 isolates. Moreover, iMDDCs with DCIR
knock-down demonstrated large (BaL), moderate (CH042.C) and
small (REJO.D12.1972) reduction in HIV-1 capture, whereas DC-
SIGN knock-down severely impaired the capture of all the three
viruses by iMDDCs. Taken together, these results imply that DC-
SIGN may play a predominant role in mucosal transmission
mediated by immature DCs.
DC-SIGN, despite having a broad glycan-binding capability, has
been shown to bind preferentially to N-linked high mannose
glycans on gp120 (Pokidysheva et al., 2006). DCIR has been
suggested to bind speciﬁcally to galactosyl residues of glycopro-
teins with an EPS motif (Glu-Pro-Ser) in the long loop (Richard et
al., 2003) while others report the binding of DCIR to fucose and
mannose (Lee et al., 2011). However, the carbohydrate structure of
gp120 recognized by DCIR remains unclear (Bloem et al., 2013).
We found that both DC-SIGN- and DCIR-mediated HIV-1 capture
could be blocked by mannan while kifunensine enhanced the
effect of DC-SIGN but not DCIR in HIV-1 capture, indicating that
mannose moieties on gp120 play an important role in DC-SIGN
and DCIR binding, although glycan speciﬁcity of DCIR remains to
be determined. Recently, it has been suggested that DCIR binding
to pathogens such as HIV-1 is inﬂuenced by the glycosylation
status of DCIR CRD (Bloem et al., 2013). However, we did not
observe statistically signiﬁcant difference between wild type and
deglycosylated DCIR in mediating HIV-1 capture (data not shown).
In general, CRD in CLRs is the main functional domain that binds to
Fig. 3. DC-SIGN is more efﬁcient than DCIR in capturing a wide range of HIV-1 isolates. 1106 parental Raji cells, DC-SIGN or DCIR stably expressing Raji cells were incubated
with 100 ng p24 of laboratory-adapted or primary Env-pseudotyped (A), T/F infectious (B), or T/F Env-pseudotyped (C) HIV-1 at 37 1C for 2 h. Cells were extensively washed
to remove unbound virus and HIV-1 p24 was measured. HIV-1 capture by DC-SIGN or DCIR expressing cells was expressed as fold enhancement to that of parental Raji cells.
Data shown are mean7SD of six independent experiments with each condition performed in triplicate. (*po0.05; **po0.01).
Table 1
Kinetic parameters of soluble proteins binding to gp140.a
Parameterb KD (M) Kon (1/ms) Kdis (1/s) X2 R2
Soluble DC-SIGN 1.43E11 2.24Eþ04 3.20E07 0.689 0.906
Soluble DCIR 1.57E08 6.19Eþ03 9.72E05 0.542 0.957
Soluble DC-SIGN CRDc 1.02E08 1.35Eþ04 1.37E04 0.841 0.955
Soluble DCIR CRD 1.89E08 6.29Eþ03 1.19E04 0.378 0.975
a Data are representative of three independent experiments.
b KD, equilibrium (afﬁnity) constant; Kon, association rate constant; and Kdis,
dissociation rate constant.
c CRD, carbohydrate recognition domain.
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carbohydrate moieties. Of interest, our study here reveals that CRD
is not the sole determinant that accounts for the difference
between the binding of DC-SIGN and DCIR to HIV-1 gp120. Other
domains of the CLRs may contribute to glycan-binding likely by
stabilizing the interaction between CRD and glycans.
The neck domain of DC-SIGN can mediate protein tetrameriza-
tion (Feinberg et al., 2005). We previously demonstrated that
integration of DC-SIGN neck domain into the bifunctional CD4-DC-
SIGN fusion proteins greatly increased tetramer formation and
resulted in signiﬁcantly enhanced avidity to HIV-1 gp120 (Du
et al., 2012). Therefore, it is very likely that tetramerization of DC-
SIGN by neck domain is important for DC-SIGN binding to HIV-1
gp120. In agreement, our results in the current study showed that
the binding activity of monomeric DC-SIGN to gp120 was severely
compromised. Tetramerization of DC-SIGN might enhance its
binding afﬁnity by stabilizing the interaction between DC-SIGN
CRD and gp120 glycans. However, the engineered tetrameric DCIR
construct did not show increased binding to gp120. Although
various factors such as inappropriate conformational rearrange-
ment following the insertion of neck domain could impact the
binding activity of DCIR, we believe that the distance between
CRDs in tetrameric DC-SIGN is crucial. The distance between the
adjacent CRDs in the crystal structure of the tetrameric DC-SIGN is
54 Å (Hong et al., 2007; Pokidysheva et al., 2006), which could
Fig. 5. The integrity of CRD is important for DC-SIGN mediated HIV-1 capture. Schematic diagram of the long loop region in DC-SIGN, DCIR and DC-SIGN chimeras (A).
According to the sequence of DCIR, 11 amino acids before EP motif were mutated in chimera 1 and 6 amino acids after EP motif were mutated in chimera 2, and all 17 amino
acids in the long loop region were mutated in chimera 3. (B and C) 293T cells were transfected with pcDNA3.1, or plasmids encoding DC-SIGN, DCIR, or DC-SIGN chimera for
48 h. 1106 cells were incubated with 100 ng p24 of BaL (B) or CH198.c (C) at 37 1C for 2 h. Cells were extensively washed to remove unbound virus before HIV-1 p24 was
measured. HIV-1 capture was expressed as fold enhancement to that of pcDNA3.1 transfected cells. Data shown are mean7SD of three independent experiments with each
condition performed in triplicate. (*po0.05; **po0.01).
Fig. 4. Tetrameric structure is important for DC-SIGN-mediated HIV-1 capture. 293T cells were transfected with pcDNA3.1, or plasmid encoding DC-SIGN, DCIR, monomeric
DC-SIGN or tetrameric DCIR for 48 h. 1106 cells were incubated with 100 ng p24 of BaL (A) or CH198.c (B) at 37 1C for 2 h, followed by extensive washes to remove
unbound virus before HIV-1 p24 was measured. HIV-1 capture was expressed as fold enhancement to that of pcDNA3.1 transfected cells. Data shown are mean7SD of three
independent experiments with each condition performed in triplicate. (*po0.05; **po0.01; ns, not signiﬁcant).
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allow DC-SIGN to crosslink glycosylation sites within a single
gp120 subunit or across multiple gp120 subunits on an envelope
spike or, less likely, across multiple spikes. While in tetrameric
DCIR, the distance between two CRDs might be different and
consequently impaired gp120 binding. Our hypothesis has been
further strengthened by the results that another tetramerization
domain GCN4 leucine zipper (Harbury et al., 1993) was unable to
enhance DC-SIGN or DCIR-mediated HIV-1 capture (data not
shown). Future study is warranted to understand the precise roles
played by DC-SIGN neck domain in gp120 binding.
The interaction between DC-SIGN and gp120 is likely to be very
complex and steric space dependent. For instance, although being
engineered to contain the neck domain of DC-SIGN, tetrameric
DCIR-expressing cells did not show any increase in mediating
HIV-1 capture. In addition, DC-SIGN containing some amino acid
mutations in the long loop region of CRD lost or demonstrated
decreased capability in HIV-1 capture. These results indicate that
not only the tetrameric structure but also the intact CRD structure
are essential. A previous study revealed that a tandem repeat of
two CV-N molecules (CVN2) had increased neutralization activity
against HIV-1, but the domain-swapped dimeric form was strict
and speciﬁc, because the carbohydrate binding sites of the CVN2
variants must be optimally positioned to efﬁciently interact with
gp120 (Keeffe et al., 2011). Similarly, during evolution and selec-
tion, the tetramer and matching CRD structure of DC-SIGN maybe
optimally contribute multiple binding positions on one tetrameric
molecule for HIV-1 virions.
Engagement of HIV-1 Env to DC-SIGN or DCIR can induce
phosphorylation of corresponding CLR in its cytoplasmic tail,
consequently activating a signal transduction pathway that con-
tributes to HIV-1 immune evasion, productive proliferation and
infection (Gringhuis et al., 2010; Lambert et al., 2011; Sarkar et al.,
2013). For instance, activation of DC-SIGN induces an immature
dendritic cell phenotype triggering Rho-GTPase activity required
for HIV-1 replication (Hodges et al., 2007). Furthermore, the ITIM-
associated signal transduction pathway of DCIR has also been
reported to enhance HIV-1 infection, and probably also affect the
immune response of HIV-1. The route and fate of HIV-1 after
capture by DCs via DC-SIGN or DCIR is an important topic worthy
of further investigation in future, but is beyond the scope of our
current study.
Conclusions
To our knowledge, this is the ﬁrst study to systematically
compare the capability between DC-SIGN and DCIR in HIV-1
capture and transfer. Although both DC-SIGN and DCIR can bind
gp120 and consequently contribute to HIV-1 capture and transfer,
DC-SIGN appears to play a predominant role over DCIR in primary
DCs and transfectants. The higher capability in HIV-1 capture and
transfer of DC-SIGN compared with DCIR is likely contributed by
DC-SIGN neck domain which forms tetramerization. Our ﬁndings
provide insights into the CLR-mediated HIV-1 capture and transfer,




All human blood samples were collected under protocols
approved by the Local Research Ethics Committee and with
informed written consents from the human subjects.
Plasmids, cells, proteins and antibodies
The laboratory-adapted env clones BaL and IIIB in pcDNA3.1
were described previously (Hu et al., 2000; Huang et al., 2012).
MWS2 env was cloned from semen of a man who was known to
have vaginal intercourse with a HIV-1 acutely infected woman (Hu
et al., 2005), while CH811 env was cloned from a blood sample
isolated from a Chinese patient as described previously (Hu et al.,
2000). The T/F env clones were kindly provided by the Centre for
HIV/AIDS Vaccine Immunology (CHAVI) (Hu et al., 2010; Keele
et al., 2008). The T/F HIV-1 infectious clones (CH042, CH067,
CH164, CH185 and CH198) were kindly provided by Professor
Beatrice Hahn (Keele et al., 2008; Parrish et al., 2013) and obtained
from AIDS Research and Reference Reagent Program, Division of
AIDS, NIH. Plasmids pNL4-3 BaLþ (containing the backbone of
NL4-3 and the env of BaL), pNL4-3.Luc.R-E-, TZM-b1, and U87-CD4.
CCR5 cell lines were from NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIH. Vector pET28a(þ) was
from Novagen. 293T and QT6 cell lines were purchased from the
American Type Culture Collection. Raji cell line was described
previously (Wu et al., 2004). Mannan was from Sigma-Aldrich.
Protein CN54 gp140 was kindly provided by Professor Robin
Shattock (Hu et al., 2013; Huang et al., 2012) and purchased from
Polymum. Anti-CD4-FITC, anti-CCR5-PE, anti-CXCR4-PE, anti-DC-
SIGN-PE, and matched isotype control antibodies were from BD
Biosciences. Anti-DC-SIGN and anti-DCIR antibodies for western
blotting were from Santa Cruz. Anti-DCIR-PE and matched isotype
control antibodies were from R&D systems.
Genetic engineering
The DC-SIGN and DCIR DNA sequences were ampliﬁed from
cDNA extracted from iMDDCs using primers listed in Table S1 and
inserted into the expression vector pcDNA3.1, respectively. Flag
label was inserted into the upstream of the N terminal of DC-SIGN
and DCIR, respectively, as described previously (Sneyd, 2009).
For constructing soluble protein expression vectors, ampliﬁed
DNA fragments were subsequently cloned into pET28a(þ) after
corresponding enzyme digestion, using primers listed in Table S1.
Monomeric DC-SIGN and tetrameric DCIR were constructed by
exchanging respective extracellular neck domain, using In-Fusion
HD Cloning Kits according to the manufacturer's instructions
(Clontech Laboratories, Takara). Chimaeras of DC-SIGN were gen-
erated using site-directed mutagenesis kit (Agilent Technologies).
All recombinant DNA clones were conﬁrmed by sequencing.
Protein expression, puriﬁcation and purity analysis
The E. coli strain Rosetta (Novagen) was used for protein
expression (Ma et al., 2004). The Rosetta bacteria with desired
protein expression vector transformation were grown in LB at
37 1C with rotation. At OD600¼0.6, bacteria were induced with
isopropyl-β-D-thiogalactoside for 4 h, and then collected and lysed
by ultrasonic treatment. Using low temperature high-speed cen-
trifuge, inclusion bodies in the lysates were collected and then
washed twice with phosphate-buffered saline (PBS) supplemented
with 1 M guanidine hydrochloride (GuHCl) and re-suspended in
denaturation buffer (20 mM Tris, 500 mM NaCl, 6 M GuHCl, 5 mM
dithiotreitol, pH 8.0). The denatured recombinant proteins were
refolded at 4 1C for 24 h in refolding buffer (20 mM Tris, 500 mM
NaCl, 3 mM CaCl2, 10% glycerol, 3 mM glutathione (GSH), 0.3 mM
glutathione disulﬁde (GSSG), pH 8.0) (Ferrer et al., 1997). After
refolding, the solutions were loaded onto a pre-equilibrated
nickel-charged chelating Sepharose Fast Flow column (GE Health-
care) and recombinant proteins were puriﬁed as described pre-
viously (Du et al., 2012), according to the manufacturer's
W. Jin et al. / Virology 458-459 (2014) 83–92 89
instructions. Puriﬁed recombinant soluble proteins were resolved
by SDS-PAGE followed by western blotting.
Preparation and culture of PBMCs and iMMDCs
Peripheral blood mononuclear cells (PBMCs) were isolated
from single buffy coats using a Ficoll-Hypaque density gradient
and stimulated with 20 U/mL interluekin-2 (R&D Systems) and
1 mg/mL phytohaemagglutinin (Sigma-Aldrich). Human immature
monocyte-derived DCs (iMDDCs) were generated from a highly
enriched population of CD14þ monocytes, as described previously
(Lambert et al., 2008; Wiley and Gummuluru, 2006). In brief,
monocytes were ﬁrst puriﬁed by negative selection from PBMCs,
using the human Monocyte Isolation kit II (Miltenyi Biotec), and
then differentiated into iMDDCs in the presence of interluekin-4
and granulocyte-macrophage colony-stimulating factor (GM-CSF)
(500 and 800 U/ml, respectively; Peprotech). At day 6, the pheno-
type of the cultured iMDDCs was conﬁrmed by FACS.
Construction of DC-SIGN- and DCIR-expressing stable cell lines
The stable Raji cell populations that express DC-SIGN and DCIR,
respectively, were generated by electroporation with the corre-
sponding constructs, using the Amaxa cell line nucleofector Kit V
(Amaxa Corproation). High cell-surface expression cells were
obtained by selection with Geneticin (800 mg/ml) and sorted
by FACS.
RNA interference
Small interfering RNAs (siRNAs) speciﬁc for DC-SIGN or DCIR
are a pool of three target-speciﬁc 19 or 20-25nt siRNAs designed to
knockdown the corresponding speciﬁc gene (Santa Cruz). 1106
iMDDCs were transfected with nonspeciﬁc or speciﬁc siRNAs,
using the human DC nucleofactor kit according to the manufac-
turer's instructions (Amaxa Corproation). After 2 days, the knock-
down efﬁcacy of DC-SIGN or DCIR was monitored by FACS and
western blotting. DC-SIGN- or DCIR-knockdown DCs were imme-
diately used for subsequent experiments.
Production of Env-pseudotyped and infectious virus stocks
Stocks of pseudotyped reporter viruses were prepared as
described elsewhere (Hu et al., 2005; Liang et al., 2012). In brief,
293T cells were co-transfected with 2 μg of HIV-1 Env or VSV-G
expressing construct and 3 μg of pNL4-3.Luc.RE plasmid using
Lipofectamine 2000 (Invitrogen) according to the manufacturer's
instructions. Infectious HIV-1 stock was produced by transfecting
plasmid of pNL4-3 BaLþ or T/F infectious clone into 293T cells
using Lipofectamine 2000. In some cases, kifunensine (100 μM)
was added into the culture for the production of HIV-1 stocks
(Eggink et al., 2010). Supernatants containing viruses were har-
vested 48 h post-transfection, mixed with heat-inactivated fetal
bovine serum (FBS) to a ﬁnal concentration of 20% (V/V), ﬁltered
through 0.45 μm syringe ﬁlters (Millipore) and stored at 80 1C.
All viral stocks were titrated by p24 ELISA.
FACS
In brief, cells were harvested, counted and washed once using
PBS with 3% FBS. 1106 cells were stained with indicated
antibodies or matched isotype controls for 30 min on ice, and
then washed twice with PBS supplemented with 3% FBS, ﬁxed
with 500 mL of 1% paraformaldehyde in PBS. The cytometric
evaluations were assessed using FACSAria III cytometer (BD) and
the data were analyzed by FlowJo software (Tree Star). For cell
sorting, 1108 cells were stained as described above and kept in
ice-cold washing buffer after staining, and sorted by FACSAria III
cytometer immediately.
Western blotting
Prepared cell lysates were resolved by 12% SDS-PAGE and
transferred to 0.45 mm polyvinylidene diﬂuoride membranes
(Millipore). Nonspeciﬁc binding sites were blocked, using 5%
non-fat milk in 0.1% Tween 20/PBS overnight at 4 1C. The mem-
brane was incubated with primary antibody against DC-SIGN
(mouse monoclonal antibody; sc-23926; Santa Cruz) at a dilution
of 1:3000, DCIR (mouse monoclonal antibody; sc-374583; Santa
Cruz) at a dilution of 1:2000, FLAG (mouse monoclonal antibody;
F1804; Sigma) at a dilution of 1:3000, or β-actin (mouse mono-
clonal antibody; sc-81178; Santa Cruz) at a dilution of 1:500, for
1 h at 37 1C. The membrane was washed ﬁve times with 0.1%
Tween 20/PBS, followed by incubation for 1 h with HRP conju-
gated goat anti-mouse secondary antibody (1:10,000; BA1050,
Boster). Following ﬁve washes with 0.1% Tween 20/PBS, the bands
were visualized by exposure to FluorChem HD2 Imaging System
(Alpha Innotech) after the addition of chemiluminescent substrate
(SuperSignals West Dura Extended Duration Substrate; 34075;
Thermo Scientiﬁc Pierce). The grayscale values of WB bands were
analyzed using software Image J.
HIV-1 capture and transfer assay
1106 iMDDCs, with or without siRNA knockdown treatment,
were incubated with 100 ng p24 of HIV-1 pNL4-3 BaLþ at 37 1C
for 2 h. After incubation, cells were extensively washed to remove
unbound viruses. For virus capture assay, washed cells were lysed
with 1% Triton X-100 and HIV-1 p24 was quantiﬁed by ELISA, as
described previously (deWitte et al., 2007; Hu et al., 2004). For
virus transfer assay, washed cells were co-cultured with autolo-
gous PBMCs (1:3 ratio) at 37 1C. The supernatants were collected
every 3 days and stored at 80 1C until virus replication was
determined by p24 ELISA.
293T or QT6 cells transfected with DC-SIGN or DCIR expressing
plasmid for 48 h, or DC-SIGN or DCIR stably expressing Raji cells
were pre-incubated in the presence or absence of mannan at 37 1C
for 1 h before exposure to Env-pseudotyped or infectious HIV-1 at
37 1C for another 2 h. Following incubation, unbound viruses were
extensively washed with PBS. For HIV-1 capture assay, washed
cells were lysed with 1% Triton X-100 and p24 was measured by
ELISA. For virus transfer assay, washed cells were co-cultured with
U87-CD4.CCR5 cells at 37 1C for 48 h, lysed and luciferase activity
was determined.
Analysis of binding kinetics
The buffer of proteins for analysis was ﬁrst exchanged into PBS
(pH 7.4) with a desalt spin column (Thermo Scientiﬁc). CN54
gp140 was biotinylated by mixing with sulfo-NHS-LC biotinylation
reagents in PBS for 30 min at room temperature according to the
manufacturer's instructions (Pierce). The interactions between
gp140 and soluble DC-SIGN, DC-SIGN CRD, DCIR, or DCIR CRD
were measured on a Forte-Bio Octet RED system (ForteBio). This
system monitors interference of light reﬂected from the surface of
a sensor to measure the thickness of molecules bound to the
sensor surface. In the current study, three parameters were
adopted to represent protein-protein binding activity: equilibrium
(afﬁnity) constant (KD), association rate constant (Kon) and dis-
sociation rate constant (Kdis). A small KD, large Kon and a small Kdis
indicate that the interactions between two tested proteins have a
strong afﬁnity, high association rate and low disassociation rate,
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respectively (Abdiche et al., 2008). The biotinylized gp140 (5 mg/
ml) was immobilized on streptavidin biosensors. After reached
baseline, sensors were dipped into different concentrations of
proteins for association and then moved into running buffer
(3 mM CaCl2, 0.1% bovine serum albumin, and 0.05% Tween 20 in
PBS, pH 7.4) for dissociation. A buffer only reference was sub-
tracted from all curves. Octet Molecular Interaction System soft-
ware was used for data analysis.
Statistical analysis
Data were presented as means7standard deviation (SD) or
standard error of the mean (SEM). Comparisons between two
groups were analyzed by 2-tailed unpaired t tests while compar-
isons among more than three groups were analyzed by One-way
ANOVA with Newman–Keuls Multiple Comparison Test. P value
o0.05 was considered statistically signiﬁcant and labeled as *,
p valueo0.01 as ** and not signiﬁcant as ns.
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